Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

2.2%

2 terminated/withdrawn out of 92 trials

Success Rate

97.3%

+10.8% vs industry average

Late-Stage Pipeline

43%

40 trials in Phase 3/4

Results Transparency

3%

2 of 73 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 4
22(25.0%)
Phase 1
22(25.0%)
Phase 2
20(22.7%)
Phase 3
18(20.5%)
N/A
4(4.5%)
Early Phase 1
2(2.3%)
88Total
Phase 4(22)
Phase 1(22)
Phase 2(20)
Phase 3(18)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (92)

Showing 20 of 92 trials
NCT06609811Phase 4Completed

The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuated Vaccine

Role: lead

NCT07530679Not ApplicableNot Yet Recruiting

Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vaccination

Role: lead

NCT07232745Phase 4Active Not Recruiting

Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine

Role: lead

NCT07035054Phase 2Completed

Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

Role: lead

NCT07025876Early Phase 1Completed

PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

Role: lead

NCT05303584Phase 4Completed

Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine

Role: lead

NCT05043259Phase 1Completed

Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine

Role: lead

NCT05204589Phase 3Completed

Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine

Role: lead

NCT06605755Not ApplicableRecruiting

Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants

Role: lead

NCT06305104Phase 2Recruiting

Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.

Role: collaborator

NCT06209398Phase 4Unknown

Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine

Role: lead

NCT01949857Phase 4Completed

The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines

Role: collaborator

NCT04341389Phase 2Completed

A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)

Role: collaborator

NCT05855408Phase 4Unknown

Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults

Role: lead

NCT04840992Phase 1Completed

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

Role: collaborator

NCT04916886Not ApplicableCompleted

A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.

Role: collaborator

NCT05694728Phase 2Completed

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Role: collaborator

NCT05680454Phase 1Completed

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Role: collaborator

NCT04566770Phase 2Completed

A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Role: collaborator

NCT05212623Phase 1Completed

A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months

Role: lead